Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
AADIAerpio Pharmaceuticals(AADI) Prnewswire·2024-03-02 05:08

Aadi Bioscience, Inc. AMPECT 试验结果 - Aadi Bioscience, Inc. 在 AMPECT 试验中展示了长期的疗效和安全性结果[1] - nab-sirolimus 对于晚期 PEComa 患者的反应持续了中位数39.7个月[2] - nab-sirolimus 的长期、持久的反应和可耐受的安全性对于患有这种罕见疾病的患者来说是个好消息[3]